Is there an oral version of tirzepatide, and what about Zepbound tablets?

Step 1: Understand what tirzepatide currently is, and what it isn't yet

Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it activates two gut-hormone pathways involved in appetite regulation and blood-sugar control. It slows gastric emptying and increases the feeling of fullness after meals. In the UK, it is licensed under the brand name Mounjaro as a once-weekly subcutaneous injection, delivered via a pre-filled KwikPen. Treatment typically starts at 2.5mg to help your system settle, then increases every four weeks or so under prescriber guidance, up to a maximum of 15mg.

There is, as of mid-2026, no oral formulation of tirzepatide available to patients anywhere in the world, a question our page on whether an oral tirzepatide exists covers in full. Eli Lilly has research programmes exploring oral small-molecule GIP/GLP-1 agonists, but nothing has reached regulatory approval. The NHS tirzepatide medicines page describes the injection as the currently licensed form. If you've seen headlines suggesting otherwise, they are almost certainly describing pipeline research, not something a prescriber can offer today.

It's easy to understand why people are searching, the prospect of avoiding a weekly injection is genuinely appealing, and the volume of news about GLP-1 medicines can make it hard to separate what exists from what's in development. You're not the only one asking this.

Step 2: Separate Zepbound from Mounjaro, and from the UK entirely

Zepbound is the name Eli Lilly uses to market tirzepatide for weight management in the United States, and our page on tirzepatide and Zepbound explains the relationship between the two in detail. It is the same molecule as Mounjaro. In the UK, Mounjaro is the licensed brand name for both the weight-management and type 2 diabetes indications, Zepbound does not exist here as a product name, and it cannot be obtained from any UK pharmacy, including online ones. Any seller offering "Zepbound" to UK customers is operating outside the UK licensing framework. That matters because the MHRA has warned repeatedly about counterfeit and unlicensed weight-loss medicines entering the country through unregulated channels.

If you've read comparisons between Zepbound and Wegovy, those are US-market articles. The relevant UK comparison is between tirzepatide (Mounjaro) and semaglutide (Wegovy). For a full breakdown of how the two molecules relate across different markets, our page on whether Zepbound and Mounjaro are the same thing covers the detail clearly.

Step 3: What IS available as an oral GLP-1 in the UK for weight loss

On 11 June 2026, the MHRA approved Wegovy in tablet form (oral semaglutide) making it the first oral GLP-1 medicine licensed for weight management in the UK, and the first in Europe. This is a meaningful development for people who prefer not to inject. The tablet is taken once daily, first thing in the morning on an empty stomach with a small amount of plain water, and you wait at least 30 minutes before eating, drinking coffee, or taking other oral medicines. No refrigeration is needed, which makes it notably travel-friendly.

The dosing ladder runs from 1.5mg up through 4mg and 9mg to a 25mg maintenance dose, with a minimum of one month at each level. In the OASIS 4 phase 3 trial, participants using the tablet achieved an average weight reduction of around 13.6% over 64 weeks, rising to approximately 17% among those who stayed fully adherent throughout the study. It is important to note that ~17% figure applies specifically to the fully-adherent subgroup, the overall trial average was 13.6%. The MHRA's news on semaglutide approvals gives the regulatory context, and our dedicated page on oral tirzepatide options and alternatives covers the current landscape in detail.

One important distinction: Rybelsus is also oral semaglutide, but it is licensed for type 2 diabetes at doses of 3mg, 7mg and 14mg, these are entirely different from the Wegovy weight-loss tablet schedule and should never be confused with it. A prescriber cannot substitute one for the other.

Step 4: What this means practically if you're exploring injectable or oral options

If you're weighing up injectable tirzepatide against oral semaglutide, or trying to understand whether an oral tirzepatide might become available soon, those are exactly the questions a prescriber can help you think through. The clinical decision depends on your medical history, your BMI, any weight-related conditions, and your personal preference about route of administration. Neither medicine is suitable for everyone, and a clinical assessment is the only way to establish which, if either, is right for you.

For a wider look at what's currently licensed and dispensed for weight management in the UK, the weight loss treatment overview is a good starting point. Both Mounjaro and the Wegovy tablet are private-prescription-only at present, the MHRA approval for Wegovy tablets was granted in June 2026, and a NICE appraisal would be needed before NHS commissioning could follow. For context on how private treatment is priced and structured, our treatment and consultation page sets out what's involved. If you'd find it useful to speak with a prescriber about your specific situation, that conversation starts with a free consultation. Speak to our prescribers and get a same-day clinical review from a real person, not software.